New Therapies of Neovascular AMD—Beyond Anti-VEGFs
AbstractNeovascular age-related macular degeneration (nAMD) is one of the leading causes of blindness among the aging population. The current treatment options for nAMD include intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). However, standardized frequent administration of anti-VEGF injections only improves vision in approximately 30–40% of nAMD patients. Current therapies targeting nAMD pose a significant risk of retinal fibrosis and geographic atrophy (GA) development in nAMD patients. A need exists to develop new therapies to treat nAMD with effective and long-term anti-angiogenic effects. Recent research on nAMD has identified novel therapeutic targets and angiogenic signaling mechanisms involved in its pathogenesis. For example, tissue factor, human intravenous immune globulin, interferon-β signaling, cyclooxygenase-2 (COX-2) and cytochrome P450 monooxygenase lipid metabolites have been identified as key players in the development of angiogenesis in AMD disease models. Furthermore, novel therapies such as NACHT, LRR and PYD domains containing protein 3 (NLRP3) inflammasome inhibition, inhibitors of integrins and tissue factor are currently being tested at the level of clinical trials to treat nAMD. The aim of this review is to discuss the scope for alternative therapies proposed as anti-VEGFs for the treatment of nAMD. View Full-Text
Share & Cite This Article
Yerramothu, P. New Therapies of Neovascular AMD—Beyond Anti-VEGFs. Vision 2018, 2, 31.
Yerramothu P. New Therapies of Neovascular AMD—Beyond Anti-VEGFs. Vision. 2018; 2(3):31.Chicago/Turabian Style
Yerramothu, Praveen. 2018. "New Therapies of Neovascular AMD—Beyond Anti-VEGFs." Vision 2, no. 3: 31.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.